Signed an Agency Agreement with Cyto-Facto Inc.

Summit Pharmaceuticals International Corporation (Head Office: Hitotsubashi, Chiyoda-ku, Tokyo, President & CEO: Katsuya Okuyama) (“SPI”) and Cyto-Facto Inc. (Head Office: Minatojima-minamimachi, Chuo-ku, Kobe, President & CEO: Shin Kawamata) (“CF”) have signed an agency agreement. Under this partnership, SPI will commence agency activities for CF’s contract manufacturing services for cell and gene therapy products, as well as CF’s SaaS business for manufacturing optimization.

 

In recent years, as the scope of therapeutic modalities has expanded, the development of biological products has increased. For cell and gene therapies, there are high expectations as new treatments, especially for cancer therapy and regenerative medicine. However, they also require highly advanced technologies and extensive expertise in manufacturing and quality control.

 

CF provides one-stop CDMO services, from process development through to commercial-scale manufacturing. CF has amassed significant expertise and a strong track record, having served as the first GMP-compliant manufacturing site in Asia for the CAR-T therapy (Kymriah® intravenous infusion). CF has also developed “CytoFactory 4.0 (CF4.0),” a cloud-based, integrated management system that significantly improves manufacturing efficiency. Its manufacturing execution management service is now available, and the full CF4.0 service will be rolled out to the market in 2026.

 

SPI provides a broad range of high-quality services to the pharmaceutical industry, from supplying research equipment and biological resources, and arranging pharmaceutical licensing and research collaborations, to supporting manufacturing for active pharmaceutical ingredients (APIs) and intermediates. In June 2023, SPI formed the “New Modalities Support Group”, strengthening its support framework for areas such as antibody, exosome, and nucleic acid therapeutics. By partnering with CF, SPI aims to further enhance its services in the field of cell and gene therapy.

 

SPI will work closely with CF for the adoption and development of cell and gene therapy products.

 

For more information about Cyto-Facto, please visit: https://www.cytofacto.com/en/

 

[Contact]
Summit Pharmaceuticals International Corporation
Discovery & Alliance Coordination Dept. New Modalities Support Group
Tel：+81-3-5220-1560
Email：alliance@summitpharma.co.jp